RMC No. 30-2022 updates the VAT-exempt medicines list under CREATE, covering specified medicines and requiring sellers to review VAT treatment.
Pharmacies, hospitals, clinics, drug distributors, importers, and VAT-registered sellers of medicines must immediately verify whether the medicines they sell, dispense, import, or purchase are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration. RMC No. 30-2022 matters because it affects the VAT treatment of medicines for cancer, diabetes, hypertension, high cholesterol, mental illness, and COVID-19, including medicines added to the VAT-exempt list, one cancer medicine identified for delisting, and one COVID-19 medicine identified for correction.
What RMC No. 30-2022 Changed
RMC No. 30-2022 publishes the full text of the letter from the Officer-in-Charge Director General of the Food and Drug Administration of the Department of Health endorsing updates to the List of VAT-Exempt Medicines under Republic Act No. 11534, otherwise known as the CREATE Act.
The practical tax consequence is straightforward but important: the BIR is recognizing FDA-endorsed updates to the list of medicines that may be treated as VAT-exempt under the CREATE Act. The affected categories are medicines for cancer, diabetes, hypertension, high cholesterol, mental illness, and COVID-19. The circular also notes that the FDA endorsement includes a cancer medicine for delisting and a COVID-19 medicine for correction in the list.
For businesses, the issue is not merely classification. VAT treatment affects pricing, invoicing, accounting entries, tax returns, input tax treatment, point-of-sale systems, and documentation during BIR audit. A medicine wrongly treated as VAT-exempt may expose the seller to deficiency VAT. A medicine wrongly treated as VATable may result in overcharging customers and incorrect tax reporting.
Who Is Most Affected by the Updated VAT-Exempt Medicines List
The most directly affected taxpayers are pharmacies, drugstores, hospital pharmacies, clinics, medicine wholesalers, medicine distributors, importers, manufacturers, and other sellers or suppliers dealing with medicines covered by the CREATE Act VAT exemption.
Hospitals and clinics should pay particular attention because their billing systems may include medicines sold or dispensed as part of patient care. If the system does not correctly distinguish between VAT-exempt medicines and VATable items or services, the taxpayer may encounter errors in official receipts, sales invoices, VAT returns, and internal revenue reporting.
Pharmaceutical distributors and importers should also review their product master lists. If a medicine has been newly included in the VAT-exempt medicines list, the VAT treatment downstream may change. If a medicine has been delisted or corrected, continuing to use an outdated tax code may cause compliance issues across invoices, purchase orders, inventory systems, and customer pricing.
CFOs, accountants, and in-house counsel should treat RMC No. 30-2022 as a compliance trigger. The relevant search and audit phrases are VAT-exempt medicines Philippines, CREATE Act VAT exemption medicines, BIR VAT-exempt drugs list, FDA endorsed VAT-exempt medicines, COVID-19 VAT-exempt medicines, and cancer medicine VAT exemption.
Key Compliance Requirements and Practical Deadlines
RMC No. 30-2022 was issued on March 16, 2022. Businesses affected by the updated VAT-exempt medicines list should treat that issuance date as the point from which their compliance review should be anchored, subject to the actual effective tax treatment of the medicines in the updated list and the applicable BIR and FDA documentation.
The circular does not state a separate grace period, transition period, or extended deadline. Accordingly, businesses should not assume that they may continue using an outdated list for pricing, invoicing, and VAT reporting. The safer compliance approach is to immediately reconcile product records against the updated VAT-exempt medicines list and identify all affected stock keeping units.
At a minimum, affected businesses should confirm which medicines have been included for VAT exemption, identify the cancer medicine noted for delisting, confirm the COVID-19 medicine noted for correction, update product tax codes, and ensure that accounting and point-of-sale systems reflect the correct VAT treatment.
For VAT-registered sellers, the compliance review should cover sales invoices, official receipts, VAT returns, inventory records, product databases, supplier and customer contracts, and any internal tax matrix used by accounting teams. Businesses should also preserve the basis for classification in case the BIR later asks why a particular medicine was treated as VAT-exempt or VATable.
Penalties and Audit Risks for Incorrect VAT Treatment
RMC No. 30-2022 itself does not create a new penalty table. However, incorrect VAT treatment may still lead to ordinary tax audit consequences under existing tax rules. If a taxpayer treats a medicine as VAT-exempt without proper basis, the BIR may assess deficiency VAT, surcharge, interest, and compromise penalties under applicable rules.
On the other hand, if a taxpayer continues to impose VAT on a medicine that should be treated as VAT-exempt, the issue may create pricing, consumer, accounting, and reconciliation problems. For pharmacies and healthcare businesses, this can also create customer complaints and require correction of invoices, receipts, and internal sales reports.
The delisting and correction components are especially important. A newly included medicine, a delisted cancer medicine, and a corrected COVID-19 medicine each require different accounting treatment. Inclusion may support VAT-exempt treatment. Delisting may remove the basis for exemption. Correction may require the taxpayer to verify whether prior descriptions, product identifiers, or classifications were inaccurate or incomplete.
What Businesses Should Do Now
First, review all medicines sold, dispensed, imported, distributed, or purchased under the categories of cancer, diabetes, hypertension, high cholesterol, mental illness, and COVID-19. These are the categories expressly covered by the FDA endorsement published through RMC No. 30-2022.
Second, coordinate among tax, accounting, procurement, inventory, pharmacy operations, and IT teams. VAT classification is not only a tax decision; it must be implemented in billing systems, point-of-sale terminals, enterprise resource planning software, product databases, and invoice templates.
Third, identify whether any medicine in inventory is affected by inclusion, delisting, or correction. Businesses should avoid relying on product category alone. The proper VAT treatment should be based on the updated list and the relevant medicine entry, not merely on a general assumption that all medicines for a disease category are automatically exempt.
Fourth, document the basis for the VAT classification. During a BIR audit, the taxpayer should be ready to show why a medicine was treated as VAT-exempt or VATable. The supporting file should include the applicable BIR issuance, the relevant FDA endorsement, internal review notes, and the date when the system tax code was updated.
Fifth, review historical transactions from March 16, 2022 onward if the business continued using an older list after the issuance of RMC No. 30-2022. This is particularly important for businesses with significant medicine sales, hospital pharmacies, and drug distributors with high-volume invoices.
Why RMC No. 30-2022 Matters for CFOs and Tax Managers
RMC No. 30-2022 is a reminder that VAT exemption for medicines is not static. The CREATE Act VAT exemption depends on the covered list, and that list can be updated through FDA endorsement and BIR publication. Businesses that sell medicines must maintain a tax classification process that can respond quickly to new BIR issuances.
For CFOs, the key risk is deficiency VAT or inconsistent reporting. For accountants, the key task is to ensure that VAT returns, sales summaries, and invoice records match the correct classification. For in-house counsel, the key concern is whether contracts, customer-facing documents, and audit files support the companyβs VAT position.
How Ablola, Saribong & Gueco Can Help
Ablola, Saribong & Gueco assists pharmacies, healthcare companies, importers, distributors, hospitals, clinics, and other regulated businesses in reviewing BIR issuances, VAT exemptions, invoicing practices, and tax compliance systems. Our team can help determine whether your medicine sales are properly classified, whether your documentation is audit-ready, and whether your accounting procedures comply with BIR requirements.
If your business sells, imports, distributes, or dispenses medicines affected by the CREATE Act VAT exemption, now is the time to review your product tax codes and supporting documents. For assistance with BIR compliance, VAT exemption review, tax audit preparation, or healthcare business tax advisory, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.